Clinical Trial Search

Primary: Number of Participants Who Died — 5; 5; 5 Participants

Primary: Freedom From Seizure — 7 individuals

Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L

Primary: Sensitivity and Specificity of ASPIRE to Detect Malarial Retinopathy in Eyes of the Subjects Clinically Diagnosed With CM — 87; 85 Percentage of participants

Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants

Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants

Primary: Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 Hours — 80.0; 93.0; 39.3 percentage of participants

Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events

Primary: Participants With Local Adverse Events (AEs) — 1; 0; 0; 2 Participants

Primary: Infection Rate — 5; 6; 3; 0 Participants

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants

Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…

Primary: Parasitological Success (MITT) — 66; 28; 4; 43 participants — p=<0.005

Primary: Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination — 0; 5; 0; 12 Participants

Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl

Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05

Primary: Minutes With Seizure on EEG — 165.2; 464.8 minutes with seizure

Primary: P. Vivax Blood Collection — 2 Participants

Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants

Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106

Primary: Incidence of Placental Malaria Infection Based on Histology — 11.58; 15.42; 15.42 percentage of pregnancies — p=0.2441

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CIS43LS Product Administration — 4; 1; 5; 3 Participants

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 — 15; 14; 15; 15 Participants

Primary: Time to First PCR-detectable Malaria Infection During the Active Detection of Infection (ADI) Phase in Groups 1 and 4 — 1.01; 1.49 Events per person year at risk — p=0.009